Pancreatitis risk for patients on gliptins
A US study in 2600 patients with type 2 diabetes hospitalised for acute pancreatitis showed exenatide (Byetta) and sitagliptin (Januvia) were associated with double the risk of acute pancreatitis compared with controls.
Professor Tim Davis, from the school of medicine and pharmacology at Fremantle Hospital, said he did not prescribe the class to patients with a history of pancreatitis. Patients were encouraged to read the inserts outlining possible side-effects.
However, the new data wasn’t